Edition:
United States

ThromboGenics NV (THR.BR)

THR.BR on Brussels Stock Exchange

3.33EUR
21 Feb 2017
Change (% chg)

€-0.08 (-2.43%)
Prev Close
€3.41
Open
€3.45
Day's High
€3.48
Day's Low
€3.33
Volume
100,875
Avg. Vol
63,952
52-wk High
€3.88
52-wk Low
€2.50

Select another date:

Fri, Jan 20 2017

BRIEF-ThromboGenics enrolls first patients in Phase II clinical study evaluating THR-317 (ANTI-PLGF) for diabetic macular edema (DME)

* The Phase II study will evaluate the safety of 3 intravitreal injections of 2 dose levels of thr-317 (4 mg or 8 mg)

BRIEF-Thrombogenics' Oncurious announces European Commission confirmed orphan medicinal product designation for TB-403 for medulloblastoma

* Oncurious announces European Commission confirmed orphan medicinal product designation for TB-403 for medulloblastoma Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Bioinvent's partner ThromboGenics initiates phase II study

* Bioinvent's collaboration partner ThromboGenics initiates phase II study with the drug candidate THR-317

BRIEF-Thrombogenics enrolls first patients in Phase II clinical study evaluating THR-317 for Diabetic Macular Edema

* Thrombogenics enrolls first patients in Phase II clinical study evaluating THR-317 (Anti-PLGF) for Diabetic Macular Edema (DME)

BRIEF-Thrombogenics transaction settlement provides for 250,000 euro payment - FSMA

* Transaction settlement for Thrombogenics NV provides for payment of amount of 250,000 euros ($264,325) and nominal publication on website of FSMA Source text: http://bit.ly/2iVhVqJ Further company coverage: ($1 = 0.9458 euros) (Gdynia Newsroom)

BRIEF-Thrombogenics Q3 cash position at 88.2 million euros

* Q3 2016 cash position at 88.2 million euros ($96.42 million) Source text: http://bit.ly/2ebOCm3

BRIEF-Thrombogenics H1 revenue down at 4.0 mln euros

* H1 revenue 4.0 million euros ($4.5 million) versus 6.0 million euros year ago

Select another date:

More From Around the Web